HealthNotableReported
5.2
Argenx Halts Phase 3 Sjögren's Study on Interim Data
Le SoirLO·BE·about 23 hours ago
MarketsReportedMedium
5.2
Argenx trial failure sinks BEL 20 by 2.68%
Argenx shares plunged 15.67% after a clinical trial failure, dragging the BEL 20 index down 2.68% to 5,379 points. KBC and Umicore also fell, while Lotus Bakeries was the only gainer. The event underscores single-stock risk in a concentrated index.
Score Breakdown
Mosaic Score5.2
Model confidence0.9
Significance0.5
Source credibility0.2
Related signals
8 foundHealthNotableReported
5.1
Argenx Vyvgart fails Phase 3 Sjögren's trial, stock likely to react
STAT NewsLO·US · BE·about 15 hours ago
MarketsNotableReported
5.0
Bel 20 drops 3.17% as arGEN-X leads selloff; KBC, Melexis fall
Le SoirLO·BE·about 13 hours ago
ScienceNotableReported
4.7
Optogenetics trial partially restores vision in retinitis pigmentosa patients
STAT NewsLO·1 day ago
MarketsReported
2.1
BEL 20 rebounds 1.29% after six-session losing streak, led by Azelis
Le SoirLO·BE·3 days ago
MarketsHighReportedAccelerating
9.5
US stocks fall as 10- and 30-year Treasury yields hit 2002 highs, oil rises
Valor Econômico·US·1 day ago
MarketsHighReportedAccelerating
9.3
US 10-Year Yield Hits 5.34%, Highest Since 2002; Equities Set to Fall
Dagens IndustriLO·US·1 day ago
MarketsHighReportedAccelerating
9.0
Ibovespa Futures Fall as Brent Surges 4% on US-Iran Escalation Fears
InfoMoney·BR · US · IR·about 17 hours ago